Sign in
Taking people in United StatesNo phase

Tracks pregnancy and infant outcomes after relugolix-containing therapy exposure

Observes pregnant women exposed to relugolix-containing therapy and their babies.

Key facts

Who runs it
Sumitomo Pharma Switzerland GmbH
Where
Wilmington, United StatesSee the site
Trial code
Registry title
Relugolix Pregnancy Registry: An Observational Study of the Safety of Relugolix-Containing Therapy Exposure in Pregnant Women and Their Offspring
Status
Recruiting
People taking part
728 people, planned
Started
8 May 2023
Expected to end
May 2033
Type of study
Observational, 2 groups
Treatments tested
  • Relugolix-Containing Product
Record updated
19 August 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The registry follows pregnant women, some who took relugolix-containing therapy during pregnancy and some who did not, and tracks outcomes for the mother, the pregnancy and the baby.

Age
Women of any age.
Sex
Women only.
Disease stage
Either a woman who took at least one dose of relugolix-containing therapy during pregnancy, or a woman with a condition for which this therapy may be prescribed who did not take it during pregnancy.
Earlier treatment
Exposed group: at least one dose of relugolix-containing therapy during pregnancy. Unexposed group: no relugolix-containing therapy during pregnancy.

Main reasons for not taking part

  • Pregnancy outcome already happened before first contact with the registry (retrospectively enrolled)
  • Exposure to known teratogens or investigational medications during pregnancy
  • Lost to follow-up

This trial only enrols pregnant participants. The registry sentence this rests on: Currently or recently pregnant

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Woman of any age
  • Currently or recently pregnant
  • Consent to participate
  • Authorization for her HCP(s) to provide data to the registry; Cohort 1
  • Exposure to at least one dose of relugolix-containing therapy at any time during pregnancy; Cohort 2
  • Diagnosis of a condition for which relugolix-containing therapy may be prescribed and who are not exposed to relugolix containing therapy at any time during pregnancy

Who cannot take part

  • Occurrence of pregnancy outcome prior to first contact with the registry coordination center (retrospectively enrolled)
  • Exposure to known teratogens and/or investigational medications during pregnancy
  • The following will be eligible for enrollment, included in supplementary analyses, but excluded from the analysis population:
  • Lost to follow-up

Where in United States

  • PPDWilmington, United StatesContact: Ronna L Chan, PH.D., M.P.H.Taking people

About the trial

What the trial wants to find out

The Relugolix Pregnancy Registry is a prospective, observational cohort study designed to evaluate the association between relugolix-containing therapy exposure during pregnancy and subsequent maternal, fetal, and infant outcomes. Data will be collected from enrolled pregnant women and the healthcare providers (HCPs) involved in their care or the care of their infants, if applicable.

The 2 groups in the trial

  • Exposed Cohort

    Pregnant women who are exposed to relugolix-containing therapy at any time during pregnancy

    Treatment: Relugolix-Containing Product

  • Unexposed Cohort

    Pregnant women with conditions for which relugolix-containing therapy may be prescribed for indications that are approved or under phase 3 development and who are not exposed to relugolix-containing therapy at any time during pregnancy

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Relugolix Pregnancy Registry: An Observational Study of the Safety of Relugolix-Containing Therapy Exposure in Pregnant Women and Their Offspring
Plain-language title
Tracks pregnancy and infant outcomes after relugolix-containing therapy exposureGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
19 August 2025